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Open access under the Ea b s t r a c t
Human tissue kallikreins (KLKs) are a group of serine proteases found in many tissues and biological ﬂu-
ids and are differentially expressed in several speciﬁc pathologies. Here, we present evidences of the abil-
ity of these enzymes to activate plasminogen. Kallikreins 3 and 5 were able to induce plasmin activity
after hydrolyzing plasminogen, and we also veriﬁed that plasminogen activation was potentiated in
the presence of glycosaminoglycans compared with plasminogen activation by tPA. This ﬁnding can shed
new light on the plasminogen/plasmin system and its involvement in tumor metastasis, in which kallik-
reins appear to be upregulated.
 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction full or partial kringle domains, including the angiostatin-like pep-Human tissue kallikreins (KLKs) are a group of secreted serine
proteases found in diverse biological tissues and ﬂuids and are dif-
ferentially expressed in several pathological conditions [1]. This
family of proteases is composed of 15 members with considerable
similarities, and their genes are localized in tandem on chromo-
some 19q13.4 [1–4]. In the last decade, the number of studies
regarding the kallikrein family has increased signiﬁcantly, with
many of the studies investigating the ability of KLKs to cleave
extracellular matrix and plasma components, including collagens,
ﬁbrinogen, gelatin, laminin, and plasminogen. The ability of KLKs
to degrade multiple components of the extracellular matrix can
promote tumor growth, metastasis and invasion [5,6].
Plasminogen is a single-chain, multidomain glycoprotein of
approximately 90 kDa, and it is composed of an N-terminal pep-
tide, ﬁve disulﬁde-linked structures known as kringle domains,
and the trypsin-like serine protease plasmin [7]. Plasminogen is
expressed as a zymogen that can be processed to plasmin by two
physiological activators, tissue plasminogen activator (tPA) [7]
and urokinase type plasminogen activator (uPA) [8], which cleave
the Arg561–Val562 peptide bond. Plasminogen is involved in con-
trolling angiogenesis through its cleavage of peptides containinger).
lsevier OA license.tides [9]. However, the primary role of plasminogen is in the coag-
ulation cascade, where it is processed to plasmin, which acts in
ﬁbrinolysis to digest various clotting components.
Previous studies have revealed that plasmin either directly
cleaves the extracellular matrix (ECM) [10] and basement mem-
brane components or indirectly contributes to cleavage by activat-
ing other enzymes that degrade the structural components [11].
This indicates a role for plasmin in tumor progression and invasion
and, consequently, metastasis. This hypothesis is reinforced by the
fact that inhibiting various components involved in ﬁbrinolysis
blocks plasmin activation and decreases tumor cell migration and
invasion [10,12]. Furthermore, over-expression of plasminogen/
plasmin system members is observed in pancreatic cancer and is
closely related to the dissociation of these aggressive cancer cells
[11]. Here, we present a study on plasminogen activation by the
KLKs in the hopes of shedding new light on the plasminogen/plas-
min system and its involvement in tumor metastasis, mainly in
which kallikreins appear to be upregulated.2. Materials and methods
2.1. Enzymes, substrates and buffers
Mature human tissue kallikreins were expressed as recombi-
nant proteins from an insect cell/baculovirus expression system,
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biochem (San Diego, CA, USA). The plasmin substrate S2251 was
obtained from Chromogenix (Milano, Italy).
2.2. Peptide synthesis
An automated bench-top simultaneous multiple solid-phase
peptide synthesizer (PSSM 8 system from Shimadzu) was used
for the synthesis of FRET (ﬂuorescence resonance energy transfer)
peptides using the Fmoc procedure with NovaSyn TGR resin (Nova-
biochem, San Diego, CA, USA) [14].
2.3. Plasminogen cleavage assay
Human plasminogen (44.5 lM) was incubated with 4.5 lM re-
combinant human tissue kallikrein 1, 3, 5, and 7 in 50 mM Tris–
HCl buffer, pH 7.5, containing 1.0 mM EDTA and 0.01% Tween-20
at 37 C for 24 h. The control assays were performed without en-
zyme. The incubations were quenched by adding SDS sample buf-
fer containing 100 mM dithiothreitol and boiled for 5 min. The
samples were run on 10% SDS polyacrylamide gels, and the protein
fragments were visualized after staining with Coomassie brilliant
blue R-250. The scanned images were stored as TIFF ﬁles.
2.4. N-terminal sequencing of plasminogen fragments
The fragments resulting from plasminogen digestion by kallik-
reins were fractionated on 10% SDS–PAGE as described above
and electrotransferred onto methanol-activated polyvinylidene
diﬂuoride membranes (Millipore, Bedford, MA, USA) in glycine-
containing transfer buffer. Glycine was removed from the mem-
brane by rinsing three times for 10 min each with 100 ml of ul-
tra-pure water. Protein bands were stained for 10 min with
0.025% Coomassie brilliant blue R-250. The bands were excised
from the membranes, and the N-terminal amino acid sequence
was analyzed with a PPSQ/23 amino acid sequencer (Shimadzu
Corporation, Tokyo, Japan).Fig. 1. Hydrolysis of plasminogen by human tissue kallikreins. (A) Lane 1, molecular we
KLK1, KLK3, KLK5 and KLK7, respectively. The N-terminal sequence of the 29 kDa band
plasminogen by human tissue kallikrein 3. Lane 1, molecular weight standard; lane 2
incubated with KLK3 for 1, 4, 10 and 24 h, respectively. The ⁄ indicates the KLK3 band; t
sequence. The ﬁve kringle domains, the site of plasminogen activation by tPA ( ), and th2.5. Plasmin activity assay
Plasmin activity was measured in microassay plates using
0.055 lM plasminogen and 0.5 lM KLK1, KLK3, KLK5 or KLK7.
Incubations were carried out in the presence of 200 lM of the
chromogenic substrate D-Val-Leu-Lys-p-nitroanilide (S2251). The
assays were performed in 50 mM Tris buffer, pH 7.5, at 37 C for
1, 4 or 24 h. As a positive control, 0.055 lM of plasminogen and
0.5 lM of tissue plasminogen activator (tPA) were combined in
the presence of the substrate D-Val-Leu-Lys-p-nitroanilide under
the same conditions. A negative control was evaluated using only
kallikreins or plasminogen in the presence of the chromogenic sub-
strate. The activity of plasmin against the chromogenic substrate
was evaluated by measuring the absorbance at 405 nm. The inﬂu-
ence of GAGs (heparin, dermatan sulfate and chondroitin sulfate,
10 lM of each) and sodium citrate (1 M) on kallikrein 3 and kalli-
krein 5 activity was also tested under the same experimental
conditions.
2.6. Statistical analysis
Statistical analysis was carried out with the Prism software
package. Statistical signiﬁcance was determined using Student’s
t-test and the Bonferroni test. The results were considered to be
signiﬁcant at P < 0.05.3. Results and discussion
To better understand the speciﬁcity of the human tissue kallik-
reins, we initiated a study to evaluate the degradation pattern of
various proteins incubated with KLKs. The degradation of plasmin-
ogen byKLKs drewour attention due to the persistent formation of a
protein fragment of approximately 29 kDa resulting from proteoly-
sis with only KLK3 and KLK5, and this fragment had not yet been re-
ported in other similar studies [5,6]. Human plasminogen was
incubated with recombinant KLK1, KLK3, KLK5, or KLK7 as de-
scribed, and Fig. 1A shows the fragments of degraded plasminogenight standard; lane 2, plasminogen; lanes 3, 4, 5 and 6, plasminogen incubated with
s in lanes 4 and 5 was determined through Edman degradation. (B) Hydrolysis of
, plasminogen incubated with preheated KLK3; lanes 3, 4, 5 and 6, plasminogen
he ( ) indicates the plasmin band. (C) Schematic representation of the plasminogen
e active plasmin location.
Fig. 2. Activity of plasmin determined by hydrolysis of the substrate S2251. The kallikreins were incubated with plasminogen and the substrate S2251, and the absorbance of
the substrate was monitored at 405 nm for 1, 4 and 24 h. The experimental conditions were described in the Section 2.
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sented almost the same proteolysis pattern, and the incubation of
plasminogen with both enzymes generated a fragment of approxi-
mately 29 kDa, which was not observed in the incubation with
KLK1 and KLK7. The proteolysis proﬁle of KLK3 and KLK5 against
plasminogenwas better demonstrated by a time course experiment
(Fig. 1B), which showed that the 29 kDa fragment appeared at 10 h
of incubation. After transferring the 29 kDa fragment to a PVDF
membrane, the N-terminal sequence was identiﬁed to contain
H2N-Val-Val-Gly-Gly-Xaa-Val-Ala. We were not able to identify
the amino acid cysteine, which was represented by Xaa.
As previously discussed, the activation of plasminogen to plas-
min occurs by cleaving the Arg-Val peptide bond (Fig. 1C) at the
site of a loop formed by a disulﬁde bridge. The N-terminal se-
quence of the 29 kDa fragment had an identical sequence to the
one that would have been generated following plasminogen acti-
vation. To verify whether the 29 kDa fragment contained plasmin
activity, each KLK was incubated with plasminogen in the presence
of the speciﬁc plasmin substrate S2251. Fig. 2 shows the progres-
sive hydrolysis of the S2251 substrate, as determined by monitor-
ing the absorbance at 405 nm for 1, 4 and 24 h. The positive control
was plasminogen in the presence of tissue plasminogen activator
(tPA). The negative control used plasminogen and the S2251 sub-
strate but omitted the KLKs. Fig. 2 reveals the difference in the
absorbance of the cleaved substrate S2251 in the presence of either
the plasminogen/KLKs or the KLKs alone. An increase in absorbance
was observed after 4 h of incubation with KLK3 and KLK5 but not
KLK1 and KLK7. Compared to the positive control, KLK3 and
KLK5 were approximately 20% as efﬁcient as tPA in activating plas-
minogen at 4 h. However, at 24 h of incubation, both KLK3 and
KLK5 showed similar activity to tPA by completely hydrolyzing
the S2251 substrate. In contrast, KLK1 and KLK7 did not produce
any detectable increases in absorbance even after 24 h, indicating
that the S2251 substrate was not cleaved.
There have been several reports discussing the hydrolysis of
plasminogen by kallikreins, indicating that these enzymes are
capable of generating angiostatin-like molecules [5]. However,
these studies did not discuss the ability of KLKs to generate the ac-
tive enzyme plasmin via plasminogen hydrolysis. Michael and col-
leagues [5] showed the capacity of KLK5 to hydrolyze plasminogen
at two different peptide bonds, Lys77-Lys78 and Arg549-Lys550,
releasing two fragments that function as angiostatin-likemolecules. In their study, plasminogen hydrolysis was monitored
for 8 h by SDS–PAGE, and they did not detect any other fragments
that were similar in size to plasmin. We believe that the amount of
plasminogen (0.5 lg) and the incubation time course (8 h) em-
ployed by Michael and colleagues were insufﬁcient to generate a
detectable amount of plasmin-related fragments for visualization
by SDS–PAGE. In another publication, Heidtmann and colleagues
[6] incubated 60 lg of plasminogen with 3 lg of human KLK3 for
6 h, and they also failed to detect any fragments related to plasmin.
In a similar experiment, we used 60 lg of plasminogen, and after
10 h, it was possible to visualize a 29 kDa protein fragment whose
N-terminal sequence was similar to the N-terminus of plasmin.
KLKs were also veriﬁed to exhibit low activity against the S2251
substrate, which is largely used for monitoring plasmin cleavage.
KLKs weakly hydrolyze the S2251 substrate and, after 24 h of incu-
bation, the change in absorbance indicated that the addition of
KLK3 and KLK5 did not signiﬁcantly alter the substrate, and the ﬁ-
nal absorbance was similar to the intrinsic absorbance of the
substrate.
As previously mentioned, because glycosaminoglycans (GAGs)
and sodium citrate improve KLK3 [15] activity, we assayed the
inﬂuence of heparin, dermatan sulfate and chondroitin sulfate on
plasminogen activation by KLK3 and KLK5. Fig. 3 shows the pro-
gression of S2251 substrate hydrolysis through monitoring the
absorbance at 405 nm for 1 and 4 h following the incubation of
plasminogen with KLKs in the presence of GAGs. Notably, both
KLK3 and KLK5 activated plasminogen with nearly the same po-
tency as tPA in the presence of heparin. Furthermore, KLK3
appeared to be more potent than tPA in activating plasminogen
in the presence of dermatan sulfate. In contrast, the addition of so-
dium citrate did not produce any noticeable improvement in plas-
minogen activation by KLKs. The ability of GAGs to improve
plasmin formation has also been described for the activation of
plasminogen by tPA [16].
GAGs can interactwith hundreds of proteins, regulatingmultiple
signaling pathways. In contrast, abnormal protein/GAG aggregates
are associated with a variety of pathological conditions, including
Alzheimer’s, diabetes and different types of cancers [17]. Thus, the
ability of GAGs to enhance KLK3 and KLK5 proteolysis against plas-
minogen, releasing active plasmin, can have implications for cancer
development, as both enzymes appear to be upregulated in some
types of cancers, mainly prostate and ovarian cancers [18–19].
Fig. 3. Plasmin activity determined by hydrolysis of the substrate S2251 in the presence of heparin, dermatan sulfate, chondroitin sulfate and sodium citrate. KLK3 and KLK5
were incubated with plasminogen in the presence of substrate S2251 and the indicated glycosaminoglycan. The absorbance of the substrate was monitored at 405 nm for 1, 4
and 24 h. The experimental conditions were described in the Section 2.
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ase with chymotrypsin-like speciﬁcity and thus most efﬁciently
hydrolyzes substrates with a hydrophobic residue at the P1 posi-
tion, manly tyrosine and phenylalanine. However, N-terminal
sequencing revealed that KLK3 activated plasminogen by cleaving
the peptide bond following an arginine residue. Therefore, we syn-
thesized the peptides Abz-APGRVVGGAQ-EDDnp, H2N-
CPGRVVGGC-NH2 and H2N-QVEPKKCPGRVVGGCVAHPHS-NH2,
which comprise the loop leading to the active site of plasminogen
(Fig. 1C). This experiment was performed to determine the kinetic
parameters of the hydrolysis. The ﬁrst peptide was prepared with
two alanines substituting for the cysteine residues, and the other
two peptides were prepared to form the disulﬁde bridge that
serves as the loop that is cleaved for plasminogen activation. How-
ever, no KLK3 or KLK5 proteolytic activity was detected against the
two peptides with the disulﬁde bridge, even in the presence of
GAGs or sodium citrate. Only the peptide that contained the two
alanines substituting for the two residues of cysteine was hydro-
lyzed by both KLK3 and KLK5 (Fig. 4). In all assays, KLK5 activity
was higher than KLK3 activity. However, due to the low activity de-
tected, it was not possible to determine the kinetic parameters Km
and Vmax, even in the presence of GAGs and sodium citrate. TheseFig. 4. Activity of KLK5 and KLK7 against the quenched ﬂuorescent peptide Abz-
APGRVVGGA-EDDnp. The enzyme activities were also assayed in the presence of
GAGs and sodium citrate.observations suggest a more complex interaction between GAGs,
KLKs and the substrate (plasminogen or synthetic peptide) and
indicate that the enhanced activity of KLK3 and KLK5 in the pres-
ence of GAGs is also dependent on the target substrate.
In conclusion, here we presented evidences that indicate the
capacity of KLK3 and KLK5 to activate plasminogen. As both KLKs
are expressed in several tissues and secreted into the circulation
and other major biological ﬂuids [3], the ability of these enzymes
to activate plasminogen could represent a new way to understand
their involvement in various pathological conditions, primarily
cancer and inﬂammation processes, in which KLKs appear to be
upregulated.
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